A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Recruiting

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Bioheng Study site, Shanghai